Free Classifieds
Home | Post Ad | My Account | Help | Affiliate Program | Local Classifieds | Just Viewed | Keyword Alerts
Username:
Password:
Affiliate Program
Post Ad
Enter your zip to find stuff near you
 
 Classifieds > Health & Fitness > MiscAffiliate Ad (info)
An affiliate ad has been posted by a person or company who markets/sells products for another person or company. The advertiser would usually receive a commission for a sale or lead generated.
- Flag
Click here to flag this ad for review or to report a problem

FDA Requests Marketing Suspension of Trasylol

Item ID#:985519Location:
Unlisted
Seller ID#:149610 Views:
771
Price:$UnspecifiedExpires:expired

This classified ad has expired

Click here to view current advertisements similar to this one.





FOR IMMEDIATE RELEASENovember 5, 2007

Media Inquiries: Peper Long, 301-827-6242Consumer Inquiries: 888-INFO-FDA
FDA Requests Marketing Suspension of Trasylol
The U.S. Food and Drug Administration (FDA) today announced that, at the agency's request, Bayer Pharmaceuticals Corp. has agreed to a marketing suspension of Trasylol, a drug used to control bleeding during heart surgery, pending detailed review of preliminary results from a Canadian study that suggested an increased risk for death.
FDA requested the suspension in the interest of patient safety based on the serious nature of the outcomes suggested in the preliminary data. FDA has not yet received full study data but expects to act quickly with Bayer, the study's researchers at the Ottawa Health Research Institute, and other regulatory agencies to undertake a thorough analysis of data to better understand the risks and benefits of Trasylol.
There are not many treatment options for patients at risk for excessive bleeding during cardiac surgery. Thus, FDA is working with Bayer to phase Trasylol out of the marketplace in a way that does not cause shortages of other drugs used for this purpose.
Until FDA can review the data from the terminated study it is not possible to determine and identify a population of patients undergoing cardiac surgery for which the benefits of Trasylol outweigh the risks. Understanding that individual doctors may identify specific cases where benefit outweighs risk, FDA is committed to exploring ways for those doctors to have continued, limited access to Trasylol.
Two weeks ago, FDA was notified that researchers with the Ottawa Health Institute stopped a study on Trasylol because the drug appeared to increase the risk for death compared to two other antifibrinolytic drugs used in the study. Antifibrinolytic drugs help slow the breakdown of blood clots and subsequent excessive bleeding. The preliminary data from this terminated study also suggested that fewer patients receiving the drug experienced serious bleeding events.
On Oct. 26, FDA issued an Early Communication about an Ongoing Safety Review of Trasylol in response to the Canadian study's termination. In 2006, FDA revised the labeling for Trasylol to strengthen its safety warning and limit its approved usage to patients at an increased risk for blood loss and blood transfusion during coronary bypass graft surgery.
###
Contact our Lawyers To Discussion Your Trasylol Case.

Anapol Schwartz Weiss Cohan Feldman & Smalley, 1710 Spruce Street, Philadelphia, PA 19103 (866)735.2792
Share
My Account
Post Ad
Local Classifieds
Help Topics
Copyright© 1999 - 2014 USFreeads. All rights reserved
Please read our Terms of service & Privacy Policy

Contact Us
Privacy Policy
Terms of Service
0

skddRsHHkAsBk
11/29/2014 9:11:57 AM UTC